Community Health Navigator Program for Coronary Artery Disease

WestView Primary Care Network, Edmonton, Canada
Coronary Artery Disease+6 More ConditionsCommunity Health Navigator Program - Behavioral
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a program that uses community health navigators to help patients with multiple long-term health conditions get the care and resources they need.

Eligible Conditions
  • Coronary Artery Disease
  • Asthma
  • Congestive Heart Failure
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Type 2 Diabetes
  • Chronic Kidney Disease
  • High Blood Pressure

Treatment Effectiveness

Study Objectives

1 Primary · 33 Secondary · Reporting Duration: Up to 36 months

Up to 12 Months
Anxiety symptoms
Depressive symptoms
Health-related quality of life
Health-related quality of life as assessed by EuroQol EQ-5D-5L
Patient activation
Patient experience of care
Perceived social support
Up to 12 months
Disease-specific intermediate health outcomes: Hypertension
General self-rated health
Health literacy
Household food security
Measure of intermediate health outcomes: Hypertension
Patient experience
Provider satisfaction
Self-reported Smoking status
Smoking status
Up to 24 months
Acute care costs
All-cause mortality
All-cause mortality rate
Continuity of care
Disease-specific intermediate health outcomes: COPD/asthma
Disease-specific intermediate health outcomes: Diabetes
Heart failure
Disease-specific intermediate health outcomes: Ischemic heart disease, chronic kidney disease, diabetes
Measure of intermediate health outcomes: COPD/asthma
Measure of intermediate health outcomes: Diabetes
Measure of intermediate health outcomes: Heart Failure
Measure of statin use for patients with ischemic heart disease, chronic kidney disease, diabetes
Medication adherence
Physician costs
Primary Care Network (PCN) multidisciplinary team access
Program costs
Up to 36 months
Acute care service use
up to 12 months
Weight

Trial Safety

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

1 Treatment Group

Intervention
1 of 1

Experimental Treatment

61 Total Participants · 1 Treatment Group

Primary Treatment: Community Health Navigator Program · No Placebo Group · N/A

Intervention
Behavioral
Experimental Group · 1 Intervention: Community Health Navigator Program · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 36 months

Who is running the clinical trial?

University of AlbertaOTHER
838 Previous Clinical Trials
386,679 Total Patients Enrolled
12 Trials studying Coronary Artery Disease
19,284 Patients Enrolled for Coronary Artery Disease
University of CalgaryLead Sponsor
727 Previous Clinical Trials
573,517 Total Patients Enrolled
10 Trials studying Coronary Artery Disease
10,535 Patients Enrolled for Coronary Artery Disease
Kerry A McBrien, MD, MPHPrincipal InvestigatorUniversity of Calgary
3 Previous Clinical Trials
455 Total Patients Enrolled
3 Trials studying Coronary Artery Disease
455 Patients Enrolled for Coronary Artery Disease

Eligibility Criteria

Age 18+ · All Participants · 0 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
References

Frequently Asked Questions

Is this medical investigation currently accepting participants?

"Per the information on clinicaltrials.gov, recruitment for this medical trial is ongoing. It was originally posted on April 1st of 2021 and its most recent update occurred on May 19th of 2022." - Anonymous Online Contributor

Unverified Answer

What is the current participant count for this clinical trial?

"Affirmative. According to the clinicaltrials.gov site, this research study is actively recruiting participants since its inception on April 1st 2021 and last amendment on May 19th 2022. The team seeks two hundred individuals from a single medical centre for the trial's duration." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.